The patent expiries are positive for OPT. Essentially the owners of Lucentis or Eylea can sell these drugs in combination with OPT. This allows them to protect their existing sales, despite them coming off patent. OPT's key patents extend to 2034.
The patent expiries are positive for OPT. Essentially the owners...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $403.8M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.5¢ | 36.0¢ | $606.6K | 1.610M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 75584 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 33006 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |